Abstract The 5, 10 methylenetetrahydrofolate reductase (MTHFR) enzyme is a catalyst in the folate metabolism pathway, the byproducts of which are involved in the remethylation of homocysteine to methionine. Methionine is a precursor for a major DNA methyl donor and is important for DNA methylation and gene regulation. Rare mutations in the MTHFR gene have been associated with autosomal recessive MTHFR deficiency leading to homocystinuria. In addition, two polymorphic variants in this gene (C677T and A1298C) have been implicated in a mild form of MTHFR deficiency associated with hyperhomocysteinemia. Mild to moderate hyperhomocysteinemia has been previously implicated as a risk factor for cardiovascular disease. Further, the presence of these variants, with and without mildly elevated levels of homocysteine, has been studied in relation to several multifactorial disorders including recurrent pregnancy loss, neural tube defects and congenital anomalies, cancer, and neurodevelopmental disorders. Given this wide spectrum of purported clinical implications and the prevalence of these polymorphisms, genetic counselors may encounter questions regarding the significance of MTHFR polymorphisms in a variety of settings. Here we present a brief background of the MTHFR polymorphisms, review of the literature regarding clinical considerations, and discussion of relevant genetic counseling aspects through case vignettes. Educational resources for patients and providers are also included.
Introduction
The methylenetetrahydrofolate reductase (MTHFR) enzyme plays a role in folate metabolism. Two polymorphic variants, C677T and A1298C, in the MTHFR gene were first discovered approximately 20 years ago and shown to lead to mild MTHFR enzyme deficiency which in turn was linked to mild to moderate hyperhomocysteinemia (Kang et al. 1991) . Since their discovery, MTHFR polymorphisms have been extensively investigated to assess for association in various medical conditions, primarily cardiovascular disease, thrombosis, pregnancy complications, neural tube defects, cancer risk, and psychiatric disease. Current guidelines by the American College of Medical Genetics (ACMG), American Academy of Family Physicians (AAFP) and the American College of Obstetrics and Gynecology (ACOG) do not endorse testing for MTHFR polymorphisms for routine risk assessment, or in specific settings, including evaluation of thrombosis risk or recurrent pregnancy loss (Hickey et al. 2013; AAFP 2012; ACOG 2013 ). Yet, several alternative medicine providers and websites purport the value of MTHFR genetic testing and recommend specific supplementation regimens to ameliorate the effects of enzyme deficiency to cure or prevent medical disorders. This has led to a great deal of controversy, as highlighted in the popular press (Bellamy 2015; Johnson 2015; Skeptical Raptor's Blog's 2015) . Since genetic counselors may encounter questions regarding the significance of MTHFR polymorphisms in a variety of settings, the goals of this manuscript are to describe the molecular genetics and biochemistry of the MTHFR enzyme; review the history of MTHFR polymorphisms' discovery and associations with disease; and provide practical case vignettes to illustrate how genetic counselors may effectively address client concerns regarding these genetic alterations. Educational resources for providers and clients are also provided.
Molecular Genetics and Biochemistry
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the folate metabolism pathway (Fig. 1) . This enzyme converts methylenetetrahydrofolate to methyltetrahdydrofolate, the primary circulating form of folate (Rozen 1996) . Defects in folate processing as a result of MTHFR deficiency have been associated with decreased blood folate levels (Tsang et al. 2015) . Circulating folate is a co-substrate for the re-methylation of homocysteine to methionine. Methionine is a precursor to Sadenosylmethionine (SAMe), which is a major methyl donor (Hickey et al. 2013) . Variants in the MTHFR gene and folate status have been shown to affect DNA methylation and gene regulation (Friso et al. 2002) . Defects in both the re-methylation pathway and transsulfuration of homocysteine to cysteine have been associated with elevated levels of plasma total homocysteine (Kang et al. 1991 ).
History of Disease Association
A rare autosomal recessive disorder, homocystinuria, caused by markedly decreased MTHFR enzyme activity was first described in 1972 (Mudd et al. 1972 ). This inborn error of folate metabolism is associated with elevated total and free plasma homocysteine, free urine homocysteine, and decreased methionine. This condition presents in infancy or early childhood with developmental delay, feeding difficulties, movement disorder, seizures, thrombosis, and psychiatric disturbance (Huemer et al. 2015) . Milder forms of the condition have been described and are associated with higher residual enzyme activity, later symptom onset, and predominantly psychiatric symptoms, intellectual disability, and movement disturbances . Patients with severe MTHFR deficiency have enzyme activity in the range of 0-34%. A majority of mutations are non-recurrent and no genotype-phenotype relationship has been identified (Huemer et al. 2015) .
Homocystinuria related to cystathionine beta synthase (CBS) deficiency is another autosomal recessive inborn error of metabolism caused by a defect in the trans-sulfuration of homocysteine to cysteine. Individuals with CBS-related homocystinuria can develop dislocated lens and/or severe myopia, skeletal features including osteoporosis, scoliosis, and chest deformities, cardiovascular disease Fig. 1 Reprinted with permission from Botto and Yang (2000) . 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. American Journal of Epidemiology, 151(9), 862-77 including premature coronary artery disease and thrombosis, and neurological differences such as developmental delay/intellectual disability, seizures, psychiatric problems (Picker and Levy 2014) .
Homocysteine may have a thrombogenic effect through inhibition of inactivation of activated factor V (Va) by activated protein C (Keijzer et al. 2007) . Moderate elevations in homocysteine (15-30 μmol/L) were first linked to a thermolabile form of the MTHFR enzyme in 1991 (Kang et al. 1991) . In this study, 50% of normal enzyme activity was identified in 17% of individuals with coronary artery disease, versus 5% of controls. The authors concluded that MTHFR thermolabile enzyme was positively associated with coronary artery disease. In 1995, Frosst et al. (1995) identified a polymorphism in the MTHFR gene, C677T (amino acid change A222V), associated with an average of 30% normal activity for homozygotes and 65% normal activity for heterozygotes. In this study, individuals who were homozygous for the C677T polymorphism had statistically significant elevation in levels of plasma homocysteine when compared to those who were heterozygous or had a wild-type genotype. However, this study did not address the association between this polymorphism and resulting vascular disease, or the influence of dietary factors.
Variant Frequency
The C677T MTHFR polymorphism is extremely common in certain racial and geographic populations. In the United States, approximately 20-40% of Caucasian or Hispanic individuals are heterozygous for MTHFR C677T (Botto and Yang 2000) . The polymorphism is less common in U.S. Blacks (~2%). In North America, Europe, and Australia, approximately 8-20% of the population is homozygous for MTHFR C677T (Botto and Yang 2000) .
Another MTHFR polymorphism, A1298C, is found in 7-12% of North American, European and Australian populations and is less common in Hispanics (4-5%), Chinese (1-4%), and Asians (1-4%) (Botto and Yang 2000) . Homozygosity of the MTHFR A1298C polymorphism leads to 60% of normal enzyme function (Rozen 1996) . Summary: Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the folate metabolism pathway (Fig. 1) . Rare mutations in the MTHFR gene are associated with an autosomal recessive inborn error of metabolism leading to homocystinuria. Two polymorphic variants, C677T and A1298C, lead to decreased enzyme function and were initially studied in relation to cardiovascular disease.
Cardiovascular Disease
Initial retrospective studies demonstrated that moderately elevated homocysteine levels were associated with a higher risk of cardiovascular disease and venous thrombosis (Clarke et al. 1991; Eldibany and Caprini 2007; Klerk et al. 2002) . In most of these studies, MTHFR polymorphism status was associated with increased risk for cardiovascular disease and elevated homocysteine in the setting of folate deficiency. Further prospective studies have not shown as strong of a relationship between homocysteine and risk of cardiovascular disease, including coronary artery disease, heart attack, and stroke (Homocysteine Studies Collaboration 2002). However, a more recent review article evaluating the role of hyperhomocysteinemia in vascular contributions to cognitive impairment and dementia found that there is sufficient evidence to implicate hyperhomocysteinemia as a mediating factor for vascular components of cognitive decline (Hainsworth et al. 2015) .
After a majority of trials showed that lowering homocysteine levels by vitamin supplementation (including folic acid, vitamin B6, and vitamin B12) did not reduce risk of cardiovascular disease, with the exception of a reduction in stroke risk noted in one meta-analysis, the role of homocysteine activity was called into question (Albert et al. 2008; Clarke et al. 2010; Huang et al. 2012; Martí-Carvajal et al. 2009 ). The U.S. Preventative Services Task Force on risk factors for coronary heart disease has stated that there is considerable uncertainty in the application of elevated homocysteine as a predictive marker for intermediate-risk individuals (Helfand et al. 2009 ). In 2010, the American Heart Association (AHA) issued a statement that the organization does not consider high plasma homocysteine to be a major risk factor for cardiovascular disease (Greenland et al. 2010) . It also states that a causal link between homocysteine levels and atherosclerosis has not been established, a statement that was supported by further meta-analysis (Clarke et al. 2012) .
Elevated homocysteine levels have also been associated with an increased risk for venous thromboembolism (VTE) (Cattaneo 2006; Den Heijer et al. 2005) . Initial studies supported a weak association between MTHFR C677T polymorphisms and an increased risk of VTE, yet the association was often population-specific and not found in North America, likely due to higher dietary intake of riboflavin and folate (Den Heijer et al. 2005) . Further studies have shown that the MTHFR C677T and A1298C polymorphisms are not independently associated with an increased risk of VTE (Bezemer et al. 2007; Gouveia and Canhão 2010) .
At least two large trials have examined the role of lowering homocysteine to prevent initial or recurrent VTE and both found no benefit to B vitamin supplementation Ray et al. 2007 ). The Thrombosis Interest Group of Canada position statement recommends against testing for homocysteine and MTHFR polymorphisms in the setting of venous thrombosis (Thrombosis Canada 2015) . Similarly, in 2013 the ACMG issued recommendations against testing for MTHFR polymorphisms in the evaluation for thrombophilia (Hickey et al. 2013 ).
Summary: Elevated homocysteine levels have been weakly associated with an increased risk for venous thromboembolism (VTE). These associations are population-specific, and not found in North America likely due to dietary intake of folate. Controlled trials have not shown that lowering homocysteine through vitamin supplementation reduces the risk of blood clots or cardiovascular disease, though supplementation may be beneficial for stroke prevention. Professional organizations in the United States and Canada do not recommend assessing homocysteine and MTHFR polymorphism status for routine evaluation of VTE or cardiovascular disease.
MTHFR and Recurrent Pregnancy Loss
There have been conflicting data regarding the effects of mild hyperhomocysteinemia in women during pregnancy. Elevated homocysteine has been observed more frequently in women with preeclampsia, placental abruption, and pregnancy loss. Data regarding the association of elevated homocysteine and recurrent pregnancy loss have been conflicting. It is plausible that hyperhomocysteinemia may be a consequence, rather than a cause, of recurrent pregnancy loss (ACOG 2013) .
Independent of elevated homocysteine, meta-analyses have not found an increased risk for recurrent pregnancy loss in women with MTHFR homozygous C677T genotype (Rey et al. 2003) . Subsequent meta-analyses stratified by geographical region demonstrated an increased odds ratio of recurrent pregnancy loss for women with homozygous C677T genotypes in Chinese populations only (Cao et al. 2013 ). There was not a significant association in the studies conducted in non-Chinese or European only populations (Ren and Wang 2006) . There was no association between A1298C genotype and recurrent pregnancy loss (Cao et al. 2013) .
The ACOG and the National Society of Genetic Counselors (NSGC) do not support MTHFR polymorphism analysis or plasma homocysteine testing in the evaluation for recurrent pregnancy loss (ACOG 2013; Laurino et al. 2005) .
Summary: There have been conflicting data regarding the association among MTHFR polymorphisms, hyperhomocysteinemia, and recurrent pregnancy loss. At this time, the ACOG and NSGC do not recommend evaluation of MTHFR polymorphism status or plasma homocysteine testing for the evaluation of recurrent pregnancy loss.
MTHFR and Neural Tube Defects
Folic acid supplementation is known to reduce risk for neural tube defects (NTD). Defects in metabolic pathways leading to homocysteine elevation and reduced circulating folate, including MTHFR enzyme deficiency, have been suspected to play a role in the development of NTD. Early studies showed a moderately increased risk for NTDs in pregnancies in which the fetus or mother [odds ratio (OR) 1.8 and 2.0, respectively] was homozygous for the C677T polymorphism (Botto and Yang 2000) . Heterozygosity for the C677T or A1298C polymorphism has been less consistently associated with neural tube defects (Wang et al. 2012b ). However, research examining folate status in mothers of NTD affected pregnancies versus controls has shown that MTHFR genotype alone does not entirely account for reduced folate levels (Molloy et al. 1998) . These findings prompted the question of whether MTHFR polymorphism screening has a role in clarifying risk for NTD in pregnancy (Finnell et al. 2002) . As early studies showed that MTHFR polymorphism status is not individually a significant risk factor for NTD and folic acid supplementation has resulted in decrease in NTD population-wide, available evidence did not support clinical utility of MTHFR polymorphism screening.
Current recommendations state that all women of childbearing age should take a multivitamin containing 0.4 mg of folic acid per day prior to pregnancy to reduce the chance of NTD (American Academy of Pediatrics, Committee on Genetics 1999; Centers for Disease Control (CDC) 1991). A higher dosage of folic acid, usually 4 mg, may be recommended for women who have had a previous pregnancy with a NTD. Though additional meta-analyses have shown a positive association between C677T genotype and risk of NTD (OR 1.23 -1.44), there have been no recommendations to increase folic acid supplementation based on MTHFR polymorphism genotype alone (Yang et al. 2015; Zhang et al. 2013 ).
Summary: There may be a positive association between MTHFR genotype and chance of NTD in a pregnancy. However, there have been no recommendations to increase folic acid supplementation, alter the type of folic acid supplementation, or to perform additional screening based on genotype alone.
MTHFR and Cancer Risk
Data regarding the association between MTHFR polymorphism status and cancer risk have also been conflicting. Early meta-analysis of MTHFR polymorphisms and colorectal cancer (CRC) risk were inconsistent though some studies suggested a protective effect of C677T homozygosity and cancer development (Hubner and Houlston 2007; Sharp and Little 2004) . Findings also suggested that colon cancer risk was lower for subjects with higher folate status and in geographical regions with increased dietary intake of folate. However, heterogeneity among the study populations complicated the interpretation of these results. A more recent meta-analysis suggested a slightly increased risk for colorectal cancer in Caucasians and Asians with the homozygous or heterozygous C677T genotype. No association was seen for Africans (Teng et al. 2013 ). The effect of folate status on cancer risk associated with MTHFR polymorphisms has lead some to propose folic acid supplementation in at-risk populations (Bailey 2003) .
Research on the association of MTHFR polymorphisms and breast cancer risk has also demonstrated weak and inconsistent results. One meta-analysis showed significant association between homozygous or heterozygous C677T status and increased chance of breast cancer (Zintzaras 2006 (Qi et al. 2010 ). In the United States, the lifetime risk to develop breast cancer in women is estimated to be 12.3% (Howlader et al. 2015) . It is important to note that other established reproductive, lifestyle, and family history risk factors, as well as known genetic predisposition syndromes (e.g., BRCA1/BRCA2), are important to consider when factoring a woman's individual risk of developing breast cancer.
Research has also linked C677T homozygous polymorphism status with increased risk for gastric cancer, with an odds ratio of 1.52 (1.31-1.77) overall (Boccia et al. 2008 ). In the portion of studies that stratified for folate status, there was an increased risk for individuals with low folate but not for individuals with high folate levels [OR 2.05 (1.13-3.72)]. Even with a slightly increased relative risk, the lifetime risk to develop gastric cancer in the United States is low (< 1%), and additional factors such as diet, smoking, and family history can also contribute to risk (Howlader et al. 2015) . Slightly decreased risk for acute lymphocytic leukemia (ALL) in children and Caucasians with the MTHFR C677T genotype has been observed (Wang et al. 2012a) . No association with the A1298C genotype was observed and there were not sufficient data to stratify by folate status. Controlled trials have demonstrated that folate supplementation can decrease plasma homocysteine, but that this does not have a significant effect on cancer incidence (Clarke et al. 2010 ).
Summary: There have been weak and inconsistent data demonstrating an association between MTHFR polymorphism status and increased cancer risk. A majority of the positive associations have been in individuals with lower folate levels. Lowering levels of homocysteine with vitamin supplementation has not been shown to affect cancer incidence in one trial.
MTHFR and Neurodevelopmental and Neuropsychiatric Conditions
Elevated plasma homocysteine and abnormalities in methylation have been studied in relation to neurodevelopmental and neuropsychiatric disease. Methionine conversion to Sadenosylmethionine (SAMe), a universal methyl donor, is important for neurotransmitter, DNA, RNA, protein, and hormone methylation. The relationship between abnormal methylation and neurodevelopment has lead to research related to the association of MTHFR polymorphisms and neuropsychiatric disease.
Overall, data regarding MTHFR polymorphisms, elevated homocysteine, and risk for neurodevelopmental and psychiatric conditions have been inconclusive. One meta-analysis showed a modest increased risk for bipolar disorder [OR 1.82 (1.22-2.70)], unipolar depression [OR 1.36 (1.11-1.67)], and schizophrenia [OR 1.44 (1.21-1.70]); there was no significant association with anxiety (Gilbody et al. 2007 ). However, later case-control studies did not show an association of MTHFR genotype and depression (Gaysina et al. 2008) . A recent updated meta-analysis regarding risk for schizophrenia and bipolar disorder showed that most significant risk was for C677T homozygosity and schizophrenia [OR 1.34 (1.18-1.53)]. There was a slightly increased chance for bipolar disorder in C677T homozygotes [OR 1.26 (1.00-1.59)]. In subgroup analyses, the association was significant in Asian and African populations but not in white populations. The A1298C variant was significantly associated with schizophrenia in Asian populations, but there was not an association with bipolar disorder (Hu et al. 2014) . A meta-analysis of eight case-control studies demonstrated a significant association between C677T polymorphism and autism spectrum disorder [TT vs. CC: OR 1.86 (1.08-3.20)] (Pu et al. 2013 ). However, when stratified by region with folate supplementation in the food supply, results were only significant for countries without food fortification.
Summary: There are inconclusive data regarding MTHFR variants, hyperhomocysteinemia, and risk for neurodevelopmental and psychiatric conditions. Subgroup analyses have shown more positive associations in populations without dietary folate supplementation.
Folate Fortification, Homocysteine, and Disease in the United States
An important qualification for interpreting the impact of MTHFR polymorphisms, homocysteine, and disease risk in the United States is the fortification of grain products with folic acid, which was implemented in January 1998. Folic acid, a synthetic form of folate, has been shown to decrease the risk of NTDs (MRC Vitamin Study Research Group 1991). Implementation of mandatory folic acid fortification in the United States has resulted in a decrease in the incidence of NTDs population-wide (Williams et al. 2015) . Given the role of folate as a co-factor in the re-methylation pathway, it has been proposed that folic acid fortification may also mask the effect of MTHFR-related hyperhomocysteinemia in the United States. Cohort analyses have demonstrated that the impact of a genetic risk factor for hyperhomocysteinemia (i.e. MTHFR C677T genotype) was substantially reduced in the folic acid-fortified compared to non-fortified population (Nagele et al. 2011) . Two studies comparing homocysteine levels in individuals homozygous for the MTHFR C677T polymorphism versus individuals with MTHFR homozygous wild-type genotype showed a significant reduction in the difference in homocysteine levels after folic acid fortification (Tsai et al. 2009; Yang et al. 2008) . Further, the prevalence of moderate hyperhomocysteinemia significantly decreased in MTHFR C677T homozygotes following fortification (Tsai et al. 2009 ).
Yet, some studies have raised concern for the potential health effects of unmetabolized folic acid (Morris et al. 2007; Troen et al. 2006) . Further, some websites and naturalist blogs caution against folic acid supplementation for individuals with MTHFR polymorphisms recommending natural folate over synthetic forms, or 5-MTHF, the active form of folic acid (Ledowsky 2015; Lynch 2016) . The authors were unable to find data to support that these alternatives are favorable. Zappacosta et al. (2013) performed a randomized control trial comparing different interventions in those with wild-type MTHFR and those with MTHFR polymorphisms and found an overall reduction in plasma homocysteine levels for those treated with either a folate-enriched diet, 5-MTHF or folic acid supplementation compared to placebo. The percentage reductions in homocysteine were greater for C677T homozygotes compared to wild-types, with the exception of the 5-MTHF groups. Further, a meta-analysis of 10 folate intervention studies demonstrated that there were no significant differences in post-intervention plasma homocysteine levels between C677T homozygotes receiving folic acid, vs. folic acid and fortified foods and/or natural food folates for a minimum of 4 weeks (Colson et al. 2015) . However, it was noted that C677T homozygotes have a lower serum folate response to shortterm supplementation compared to individuals with wild-type genotype.
At this time, there is not conclusive evidence linking unmetabolized folic acid to adverse health outcomes nor is there is support to guide recommendations based on MTHFR genotype alone. Nutritionists have suggested dietary modifications to ensure adequate intake of folate-dense foods as well as folic acid supplementation where indicated, especially for populations not consuming-folic acid fortified foods (Bailey 2003) .
Summary: Studies support the conclusion that folate supplementation in the United States reduces the effect of the MTHFR C677T polymorphism on plasma homocysteine levels in this population. There is not published evidence to suggest that supplementation with folic acid is harmful to those with MTHFR C677T, or that supplementation with natural forms of folate or 5-MTHF is preferable.
How to Counsel for MTHFR: Case Vignettes
A 37 year-old woman reports a previous pregnancy affected by neural tube defect. Her sister had MTHFR genotyping due her own history of recurrent pregnancy loss and was found to be a C677T homozygote. The patient requested MTHFR genotyping from her obstetrician revealing that she was also C677T homozygote. She presents with questions regarding the dosage of folic acid during current pregnancy and the possible relationship of MTHFR genotype status to past pregnancy with neural tube defect.
& This patient can be informed of the standard recommendations for folic acid supplementation given her past history of a pregnancy with neural tube defect, which is typically 4 mg folic acid per day. Research has demonstrated that after controlling for MTHFR genotype, mothers of pregnancies affected by NTD had significantly reduced folic acid intake and higher levels of homocysteine compared to controls (Molloy et al. 1998 ). This supports that folic acid status, rather than MTHFR genotype alone, is an important factor for assessing risk for NTD. At this time, there would be no recommended change to folic acid supplementation based on her MTHFR status. However, the importance of appropriate folic acid supplementation should be reinforced, particularly for individuals who may have lower folate due to dietary restrictions (i.e., avoidance of grain products due to Celiac disease or gluten intolerance). There are several biomarkers for folate status available, either through direct folic acid measurement in serum, plasma, or red blood cells (RBCs) or through surrogate markers of deficiency such as plasma homocysteine (Green 2011) . The World Health Organization has issued guidelines on threshold RBC folate concentrations for preventing NTD at the population level, however there are no specific guidelines for individual assessment of folate status in this setting . & This patient may have been at slightly higher risk (OR up to 2.0) than the general population due to MTHFR homozygote status, though the absolute risk was low as the general population risk is approximately 1/1000. Neural tube defects are multifactorial in origin. This patient has a higher risk, approximately 4%, for neural tube defects in a future pregnancy due to her pregnancy history. Prenatal screening options should be reviewed.
A 65 year-old woman presents for MTHFR genetic testing. There is a family history of autism spectrum disorder in her grandchild and Alzheimer's disease in her father. Another relative underwent MTHFR genotyping revealing compound heterozygosity for the C677T/A1298C polymorphisms. The patient has concerns about relationship of MTHFR genotype to the family history of neurodevelopmental and psychiatric conditions and whether there is specific management for these conditions. & The genetics of depression, Alzheimer's disease, and autism spectrum disorders are complex. The concept of genetic polymorphism and the frequency of MTHFR variants in the general population, as well as the relationship of MTHFR deficiency to hyperhomocysteinemia, should be discussed. A recent review article cites sufficient evidence to support a mediating effect of hyperhomocysteinemia and the vascular contributions to cognitive impairment and dementia (Hainsworth et al. 2015) . However, more research is needed to determine the effect that B-vitamin supplementation can have on lowering plasma homocysteine levels and risk for cognitive decline with aging. The conflicting findings related to MTHFR and neurodevelopmental illness can be explained. There is no specific management based on the MTHFR result.
A 57 year-old man presents due to a family history of coronary artery disease and early-onset myocardial events in his father and two of three paternal uncles. He underwent MTHFR genotyping that demonstrated homozygous C677T status. Total plasma homocysteine has been mildly elevated. Patient presents with concerns regarding potential cardiovascular outcomes and mortality given genotype and family history. Patient also has questions regarding treatment for elevated homocysteine and the role of vitamins and supplements.
& Information regarding the conflicting evidence of MTHFR polymorphism status and elevated homocysteine can be reviewed. Vitamin B6, B12, and folic acid supplementation may reduce blood total homocysteine levels, but there is no evidence to support that this affects cardiovascular outcome. Patient can be counseled that there is no impact on mortality given MTHFR polymorphism status. The importance of general cardiovascular disease prevention based on this patient's family history should be emphasized. The patient can be referred to the AHA's patient publication on homocysteine and cardiovascular disease (see Table 2 ). 
Conclusion
Pathogenic mutations in the MTHFR gene are associated with an autosomal recessive inborn error of metabolism leading to homocystinuria. More mild MTHFR enzyme deficiencies have been associated with moderately elevated total plasma homocysteine. Two MTHFR polymorphisms, C677T and A1298C, reduce enzyme activity in either the homozygous or compound heterozygous state. Reduced enzyme activity is associated with elevated homocysteine and potential methylation abnormalities. The MTHFR variants have been studied in relation to several multifactorial disorders including cardiovascular disease, cancer, recurrent pregnancy loss, NTDs and other congenital anomalies, and neurodevelopmental disorders. Results of these studies have been conflicting and the clinical significance of these polymorphisms is uncertain. Further, systematic reviews of the clinical evidence may be subject to publication bias in that small or negative-association studies may not be represented in the literature. Given the absence of clinical utility, the AHA does not recommend testing for MTHFR polymorphisms or homocysteine as risk factor for coronary artery disease or venous thrombosis (Greenland et al. 2010) . In addition, the ACOG does not recommend testing for the MTHFR polymorphisms in the evaluation for recurrent pregnancy loss. Finally, the ACMG recommends against testing for the MTHFR polymorphisms. A summary of these guidelines is available in Table 1 .
While B vitamin supplementation (including folate or folic acid, vitamin B6, and vitamin B12) has been shown to reduce total plasma homocysteine, it is not clear that this has any effect on cardiovascular disease or other health outcomes. Therefore, presence or absence of MTHFR polymorphisms does not significantly impact medical management, particularly in the case of common, complex diseases. Despite the lack of demonstrated clinical utility in most populations, patients may encounter information through varied sources which may cause concern for a myriad of health conditions should an individual be found to have the MTHFR polymorphisms. Genetic counselors can be a resource for both patients and providers regarding the available clinical evidence on the impact of MTHFR polymorphisms on health. Appropriate educational resources for patients and providers are included in Table 2 
